On February 17, 2026, Telomir Pharmaceuticals reported significant tumor cell mortality in triple-negative breast cancer models using their drug Telomir-Zn, showing near-complete cell death in some types. They are progressing towards an Investigational New Drug application expected in Q1 2026, indicating important steps in cancer treatment development.